AIM
AGIO icon

Acrospire Investment Management’s Agios Pharmaceuticals AGIO Stock Holding History

Acrospire Investment Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,100
Closed -$46K – 2187
2016
Q4 		$46K Buy
1,100
+600
+120% +$31.5K 0.02% 1438
2016
Q3 		$26K Buy
500
+100
+25% +$4.36K 0.02% 1401
2016
Q2 		$17K Buy
+400
New +$19.8K 0.01% 1577

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Acrospire Investment Management's AGIO Position: Q1 2017 in Review

Acrospire Investment Management sold out of Agios Pharmaceuticals (AGIO) in Q1 2017, closing a stake of 1,100 shares — an estimated $46K sold.

Acrospire Investment Management first reported a position in AGIO in Q2 2016 and held it in 3 quarters. The position peaked at $46K in Q4 2016. 156 funds tracked by Wall St. Rank hold AGIO as of Q1 2017.

  • Acrospire Investment Management reported no remaining Agios Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 1,100 Agios Pharmaceuticals shares in Q1 2017, an estimated $46K.
  • Acrospire Investment Management first reported a position in Agios Pharmaceuticals in Q2 2016 and held it in 3 quarters.
  • Acrospire Investment Management's Agios Pharmaceuticals position peaked at $46K in Q4 2016.
  • 156 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.